Fig. 7

Characterization of Immune Infiltration in PDAC. A Heatmap illustrating cell type compositions and activities of selected individual gene/proteins and pathways across 5 immune clusters. The heatmap in the first section illustrates the immune/stromal signatures from xCell. RNA and protein abundance of immune-related markers and GSVA scores based on mRNA data for biological pathways upregulated in different immune groups are illustrated in the remaining sections. B Kaplan–Meier curves for overall survival based on immune clusters (log-rank test). C Key upregulated pathways based on RNA-seq for each immune cluster showing in the annotation boxes. D Boxplot illustrating blood glucose among Im-I, Im-II&III and Im-IV&V (one-way ANOVA). E Kaplan–Meier curves for overall survival based on blood glucose high patients (n = 26) and blood glucose low patients (n = 26) (log-rank test) involved in immune clusters. F FH amplification status in 3 immune clusters (Fisher’s exact test). G Boxplot illustrating FH protein expression among Im-I, Im-II&III and Im-IV&V (one-way ANOVA). H The heatmap indicating the cis-effect of FH amplification (Spearman’s correlation). I Heatmap illustrating 3 key enzymes’ expression among Im-I, Im-II&III and Im-IV&V (right). These key enzymes are involved in TCA cycle (left). J Spearman-rank correlation of the abundance of 3 ATP synthases and FH (Spearman’s correlation). K Boxplot indicating blood glucose of patients with FH amplification and FH wild type (Wilcoxon test). L, M Boxplots indicating glucose transporter SLC4A2 protein expression of patients with FH amplification and FH wild type (L) (t test) and among 3 immune clusters (M) (one-way ANOVA). N Spearman-rank correlation of the abundance of SLC4A2 and blood glucose (Spearman’s correlation). O Distribution of monocytes and cDC polarization in PDAC with different FH statuses (Wilcoxon test). P Heatmap illustrating cDC, macrophage M2 and monocytes markers expression (left) and their correlation with FH abundance (right). Q Kaplan–Meier curves for overall survival based on cDC score high patients (n = 27) and cDC score low patients (n = 27) (log-rank test) involved in immune clusters. R The systematic diagram summarizing the impact of the amplification of FH on blood glucose and tumor microenvironment. ****p < 1.0E−4, ***p < 1.0E−3, **p < 1.0E−2, *p < 0.05, ns > 0.05